Evaluating the Advantages of Upfront Enfortumab Vedotin Dose Reduction in Urothelial Cancer

Ramy Sedhom, MD, Ryan Chow, MD, and Ronac Mamtani, MD, MSCE, discuss dose reducing enfortumab vedotin to improve tolerability, without in patients with bladder cancer

Real-world enfortumab vedotin dose reductions reduced treatment interruptions without significantly affecting OS in advanced urothelial carcinoma.

Ryan D. Chow, MD, discusses real-world data showing that upfront enfortumab vedotin dose reduction can improve tolerability without affecting survival.

Ryan D. Chow, MD, PhD, Ronac Mamtani, MD, MSCE, and Ramy Sedhom, MD, spotlight a real-world analysis of upfront enfortumab vedotin dose reduction in bladder cancer.